On April 8, 2024 Glycotope GmbH, a biotechnology company utilizing a proprietary platform technology to developing antibodies against proteins carrying tumor-specific carbohydrate structures, reported that it will present its platform approach and GlycoTarget database in a poster presentation at the 2024 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Meeting, being held in San Diego, California, United States, between 05-10 April 2024 (Press release, Glycotope, APR 8, 2024, View Source [SID1234641867]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Patrik Kehler, Chief Scientific Officer of Glycotope GmbH commented: "At Glycotope, we have established a standardized process for the data collection and prioritization of potential protein/carbohydrate combined glycoepitopes (GlycoTargets). We look forward to attending AACR (Free AACR Whitepaper) to present our workflow and corresponding database to leading cancer research experts, illustrating how this information is subsequently used for the targeted discovery of antibodies that bind to our GlycoTargets, offering increased tumor-specificity compared to simple protein targets."
Poster details are as follows:
Abstract: Download here
Title: Platform approach to develop antibodies specifically recognizing cancer-associated glycoforms
Abstract Number: 5896 Link
Session Date and Time: Tuesday Apr 09, 2023 1:30 PM – 05:00 PM PDT
Location: Poster Section 25, Poster Board Number 10
Contact Information:
Glycotope GmbH
Dr. Patrik Kehler (CSO)
Phone: +49 30 9489 2600
Email: [email protected]